1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Merck & Co's Viralytics Buy Puts Oncolytic Viruses Back In Spotlight

 
• By Kevin Grogan

The US major is spending $394m to get hold of Cavatak, an immunotherapy that it hopes will work well in combination with the anti-PD-1 blockbuster Keytruda.

Merry-go-round
All aboard: Merck & Co is the latest big pharma to take part in M&A this year • Source: Shutterstock

Merck & Co. Inc. has jumped on the merger and acquisitions merry-go-round to snap up Australia's Viralytics Ltd. and broaden its research efforts in oncolytic virus therapy.

The US giant is paying A$502m ($394m), or A$1.75 per share, which represents a premium of 160% to the Sydney-headquartered...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer